Change in the total number of shares and votes in Recipharm AB (publ)

As of 29 May 2020, the total number of shares in Recipharm AB (publ) (“Recipharm”) amounts to 72,300,679 shares, divided into 15,222,858 shares of series A and 57,077,821 shares of series B. The total number of votes in Recipharm as of 29 May 2020 amounts to 209,306,401.

The number of shares and votes in Recipharm has increased as a result of the directed share issue of 4,524,886 shares of series B raising approximately SEK 500 million to Recipharm before issue costs.


For more information please visit or contact:
Thomas Eldered, CEO,, telephone: +46 8 602 52 10

This information is published in accordance with Chapter 4, Section 9 of the Swedish Financial Instruments Trading Act (SFS 1991:980). This information was submitted for publication on 29 May 2020, at 08:00 am CET.

About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s annual turnover is approximately SEK 11 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.

For more information on Recipharm and our services, please visit